Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
about
Differential PKA activation and AKAP association determines cell fate in cancer cellsImplications of Insulin-like Growth Factor 1 Receptor Activation in Lung CancerThe adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyTargeting the insulin-like growth factor pathway in hepatocellular carcinomaHeterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibodyInsulin-like growth factor system in cancer: novel targeted therapiesHigh expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathwaysWhole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology GroupCharacterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R).Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibodyTargeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures.Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachDevelopment of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axisTargeted therapies for adrenocortical carcinoma: IGF and beyond.Defining the pathway to insulin-like growth factor system targeting in cancer.IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.IGF-1 induces expression of zinc-finger protein 143 in colon cancer cells through phosphatidylinositide 3-kinase and reactive oxygen species.Targeted Therapy of Ewing's Sarcoma.Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell linesGenetic studies reveal the role of the endocrine and metabolic systems in aging.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trialAnticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxygenase-2-driven pancreatic neoplasia.A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityFAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cellsPrimary dumbbell-shaped Ewing's sarcoma of the cervical vertebra in adults: Four case reports and literature reviewEfficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts
P2860
Q24337554-84D4FC8C-94BE-404F-A677-190126E35FA5Q26740210-BBB55AB9-CAD2-4969-8B55-F01B2AECE22DQ27000467-294FED88-0D1E-4229-8BB9-0CFD37725AE6Q27006846-F8D4E136-8881-4AD2-A16F-00A82CA082B6Q27306977-16409BAF-0248-4D4C-9B2D-AD0413832177Q28081603-37A45D6C-DC94-4162-A2C2-4A9913284E2FQ28476277-3DD5DA2F-0FF6-4437-A1E8-0F2946CE49DBQ30412634-CB8876A9-E3ED-41C2-B609-0095B9910112Q33398380-F7D27195-7871-4059-B36F-795D03814909Q33398810-ACFC60F6-637A-4D32-8B63-4F003DC50FEAQ33408460-5CB451AD-86ED-4617-9697-18BB85E76DFFQ33500359-6C7B2BA7-E7C3-48B4-9B22-BD829E9C2139Q33636283-2330AB71-7B2B-4294-A7FC-A46F7F51BC81Q33707416-3134C00D-F98B-4888-9F50-B4916CFF3481Q33873775-E54E59D7-870D-4196-88CC-8C310D6CF86CQ33921296-D815D095-0A77-4EC2-BD26-653FAECC2FC7Q33925323-1013A0C4-4993-4CE0-9278-F7780A516D1EQ33927952-1758A9F8-FE0E-4396-9D4E-5974267806A7Q33959016-D305D21C-ED12-4EE9-A1A9-D5DBE04FE4C6Q34055933-5AC89D01-FD65-4DCD-9218-682358E299A7Q34101433-B8CE1080-D135-4F77-B44A-E8AB44EFCD23Q34107722-A82EB39C-2E5C-4631-81F3-F490CD91DBB8Q34159954-60968A8F-DFB4-41EF-A080-AADE4DA3A4FCQ34172489-D0AE48AB-5686-4215-AC96-2220E92C8E20Q34254212-D38983D2-94CF-40B3-9746-85ACEDCAB67AQ34262377-C13CC44F-CAC8-47BC-BA3A-7835BB50EFF8Q34333651-BDAE8965-5F13-4E1B-8777-DCFD90BD7B8CQ34391968-8898D302-B3B0-4728-BD2C-80E935CD50F3Q34406479-A387C478-CDEE-4DA5-8D18-682F2089018EQ34630640-01A26197-58F8-4FA9-8A41-67619BD3E86AQ34664129-1FE0E145-5EB2-4626-8530-839F9FE90459Q34984126-EE266ACB-8607-4552-9017-13340494258AQ35050195-02AE2745-149E-4A76-BC17-DC1A83EE1DD5Q35058305-5D8A391E-23AD-47CF-B79A-4DECE5ED165CQ35091299-9C36A524-0138-4D1E-B60C-9B978E8169CAQ35146077-5FFD2387-D1BD-44D7-83AA-D43CA3E198B7Q35741551-49E08178-F6A1-420F-9A8C-AC74347435DDQ35995484-191E3BE8-0E59-4298-A23D-5BF9E20B2C2CQ36019729-DA52DD53-6BAF-4CCD-B855-E3E6E8AABB31Q36084192-2813FDEE-00DA-4459-B66C-E3F173FB6BCB
P2860
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Early drug development of inhi ...... rom the first clinical trials.
@ast
Early drug development of inhi ...... rom the first clinical trials.
@en
type
label
Early drug development of inhi ...... rom the first clinical trials.
@ast
Early drug development of inhi ...... rom the first clinical trials.
@en
prefLabel
Early drug development of inhi ...... rom the first clinical trials.
@ast
Early drug development of inhi ...... rom the first clinical trials.
@en
P2093
P2860
P1476
Early drug development of inhi ...... rom the first clinical trials.
@en
P2093
Jordi Rodon
Robert Jean Ferry
Victoria DeSantos
P2860
P304
P356
10.1158/1535-7163.MCT-08-0265
P577
2008-09-01T00:00:00Z